Deep Brain Stimulation (DBS)

Definition and Mechanism of Action

Deep Brain Stimulation (DBS) is an invasive neuromodulation technique involving the surgical implantation of intracerebral electrodes in specific areas of the limbic system or fronto-striatal circuits implicated in mood regulation. It is neurologically approved for movement disorders (e.g., Parkinson’s disease) and is used experimentally and off-label in treatment-resistant major depression.

The procedure consists of the stereotactic insertion of two electrodes connected to a pulse generator implanted in the chest, similar to a pacemaker. The delivered electrical impulses, either continuous or cyclic, modulate neuronal activity in the target structures by reducing pathological hyperactivation or stimulating hypoactive regions.

The main target areas studied in depression include:

• Subgenual anterior cingulate cortex (Brodmann area 25): hyperactive in depressed patients and involved in negative affective processing;
• Nucleus accumbens: a key structure in motivation, reward, and goal-directed behavior;
• Anterior limb of the internal capsule and ventral striatum: involved in fronto-limbic circuits and emotional-cognitive control;
• Mediodorsal thalamus and posterior hypothalamus: newer targets for complex affective and somatic symptoms.

The rationale for DBS in depression is to restore functional balance in dysfunctional brain networks, by acting deep within circuits otherwise unreachable by external or pharmacological stimulation. Effects are gradual, with improvements appearing over weeks or months, but may persist over time in responders.

Clinical Indications

DBS is a highly selective procedure, reserved for patients with extreme treatment-resistant major depression who have failed to respond to:

• At least 4–6 antidepressants from different classes at adequate doses and durations;
• Structured psychotherapy delivered by trained professionals;
• ECT and/or rTMS, with no significant response or early relapse;
• Combined approaches (pharmacologic and somatic) with documented failure.

Selection criteria include:

• Chronic depressive episode lasting more than 2 years with severe functional impairment;
• No active psychosis, substance abuse, or dementia at the time of evaluation;
• Good insight, compliance, and family support for postoperative management;
• Thorough neuropsychiatric and neurosurgical evaluation, with documented informed consent.

DBS is indicated only in highly specialized centers with expertise in resistant psychiatry and functional neurosurgery. It is currently considered a compassionate or experimental treatment, reserved for extreme cases and implemented under clinical trial or regulated off-label frameworks.

Side Effects and Risks

DBS carries non-negligible surgical risks and potential side effects related to both implantation and chronic brain stimulation. Major complication rates range from 2% to 5%, while minor adverse events are more common but generally reversible or manageable.

Surgical risks include:

• Intracranial hemorrhage (<1–2%), with possible serious neurological outcomes;
• Implant site infection (<5%), possibly requiring device removal;
• Electrode displacement or malfunction;
• Pain, hematoma, or local irritation at the chest generator site.

Stimulation-related side effects depend on the target area and electrical parameters:

• Mood alterations (euphoria, apathy, dysphoria, anxiety);
• Sleep or eating disturbances;
• Behavioral or cognitive changes, especially disinhibition or slowing;
• Transient effects on speech, balance, or sensation (due to temporary or misdirected stimulation).

Continuous monitoring and personalized adjustment of stimulation parameters help mitigate these effects in most cases. Close collaboration among the psychiatrist, neurologist, and neurosurgeon is essential.

Clinical Effectiveness

Evidence for the efficacy of DBS in depression remains limited but promising. Pilot studies and controlled trials have reported response rates between 40% and 60% in selected patients, with clinically meaningful remission rates of 25–30%.

Benefit tends to be progressive and cumulative, with improvements emerging after 3–6 months and maintained over time in the absence of complications. Choice of target site, quality of implantation, and accuracy of stimulation are critical factors.

DBS may be especially helpful in cases characterized by:

• Persistent suicidal ideation refractory to other treatments;
• Severe anhedonia and deep limbic hypoactivity as shown in functional neuroimaging;
• Prolonged resistance to all conventional therapies with marked global functional impairment.

Recommendations and Future Directions

DBS is not yet approved as a standard treatment for depression in many countries, but it is considered an emergency strategy for extreme refractory cases within clinical trials or compassionate use programs. The CANMAT and APA guidelines mention it as an experimental option for patients who have exhausted all available therapeutic alternatives.

Looking forward, technological advances (e.g., adaptive DBS with real-time feedback), advanced functional mapping, and identification of predictive biomarkers may enhance patient selection and optimize outcomes. Access to DBS remains limited to highly specialized centers with rigorous pre-implant assessment protocols.

References
1. Mayberg HS et al. Deep brain stimulation for treatment-resistant depression. Neuron. 2005;45(5):651–660.
2. Holtzheimer PE et al. Subcallosal cingulate deep brain stimulation for treatment-resistant depression: a multisite, randomized, sham-controlled trial. Lancet Psychiatry. 2017;4(11):839–849.
3. Lozano AM et al. Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression. Biol Psychiatry. 2008;64(6):461–467.
4. Bergfeld IO et al. Deep brain stimulation of the ventral anterior limb of the internal capsule for treatment-resistant depression. JAMA Psychiatry. 2016;73(5):456–464.
5. Dougherty DD et al. A randomized sham-controlled trial of deep brain stimulation of the ventral capsule/ventral striatum for chronic treatment-resistant depression. Biol Psychiatry. 2015;78(4):240–248.
6. Bewernick BH et al. Nucleus accumbens deep brain stimulation for treatment-resistant depression: a three-year follow-up study. Neuropsychopharmacology. 2012;37(9):1975–1985.
7. Schlaepfer TE et al. Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression. Neuropsychopharmacology. 2008;33(2):368–377.
8. Williams NR et al. Five-year follow-up of bilateral subcallosal cingulate deep brain stimulation for treatment-resistant depression. Am J Psychiatry. 2016;173(6):600–606.
9. Fins JJ et al. Ethical considerations in the use of DBS for psychiatric disorders. Ann N Y Acad Sci. 2010;1180:112–126.
10. Lipsman N et al. Neurostimulation for treatment-resistant depression: current status and clinical implications. Curr Psychiatry Rep. 2020;22(7):36.